Eva Temkin
Partner
King & Spalding FDA and Life Sciences
A partner in the King & Spalding FDA and Life Sciences practice, Eva provides strategic counsel to clients on a wide variety of FDA-regulated products, ranging from biosimilars to cell and gene therapies and complex combination products. Eva advises pharmaceutical and biotechnology companies at every stage of product development and life-cycle, from data generation (including clinical investigations and real-world evidence) to application submissions, exclusivity matters, and dispute resolution.
Before joining King & Spalding, Eva acted as Director for Policy at the FDA’s Office of Therapeutic Biologics and Biosimilars, where she oversaw regulatory policy related to biosimilars and other therapeutic biologics. Additionally, as Associate Chief Counsel at the FDA’s Office of Chief Counsel, Eva provided strategic counseling to FDA’s biomedical product centers on a wide range of drug, biologic, and combination product issues.